PenumbraNYSE: PEN

The third-quarter results reflect another strong performance by Penumbra's U.S. thrombectomy business.

Penumbra, Inc. (NYSE:PEN ) Q3 2024 Earnings Conference Call October 30, 2024 4:30 PM ET Company Participants Cecilia Furlong - Director of Business Development and Investor Relations Adam Elsesser - Chairman and Chief Executive Officer Maggie Yuen - Chief Financial Officer Jason Mills - Executive Vice President of Strategy Conference Call Participants Richard Newitter - Truist Securities Robert Marcus - JPMorgan Joanne Wuensch - Citi Michael Sarcone - Jefferies Samantha Kurtz - Piper Sandler Michael Kratky - Leerink Pito Chickering - Deutsche Bank Michael Matson - Needham Operator Good afternoon. My name is Jeremy, and I will be your conference operator today.

While the top- and bottom-line numbers for Penumbra (PEN) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Penumbra (PEN) came out with quarterly earnings of $0.85 per share, beating the Zacks Consensus Estimate of $0.69 per share. This compares to earnings of $0.67 per share a year ago.

The latest news from the lab, plus an analyst's bullish move, combined to put some zip in the company's shares.

ALAMEDA, Calif. , Oct. 2, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the third quarter 2024 after market close on Wednesday, October 30, 2024 at 4:30 PM Eastern Time.

A researcher initiated coverage of the medical device maker with a confident buy recommendation. He sees multiple positive factors that should propel its growth.

Penumbra receives the CE Mark approval for Lightning Flash 2.0 and Lightning Bolt 7 in Europe.

Latest computer assisted vacuum thrombectomy (CAVT) technologies combine superior catheter design with the latest dual clot detection computer algorithms designed to restore blood flow quickly Lightning Flash™ 2.0 will be the most advanced thrombectomy system on the European market to address venous and pulmonary thrombus Lightning Bolt™ 7 is designed to enhance the ability to rapidly remove blood clots in the arteries with modulated aspiration, addressing conditions such as acute limb ischemia (ALI), hibernating thrombus and visceral occlusions ALAMEDA, Calif. , Sept. 16, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced it has secured CE Mark in Europe for the latest computer assisted vacuum thrombectomy (CAVT) technologies – Lightning Flash™ 2.0 and Lightning Bolt™ 7.